Featured Research

from universities, journals, and other organizations

Determining Genetic Signature Of Lung Tumors Can Help Guide Treatment

Date:
May 22, 2008
Source:
Massachusetts General Hospital
Summary:
The first US clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed.

The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning.

Related Articles


"This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment," says Lecia Sequist, MD, MPH, of the MGH Cancer Center, who led the study. "It is an exciting glimpse into what we hope is the future of cancer care. Instead of a 'one size fits all' therapy, we are moving towards finding the best treatment for each patient."

The most common form of lung cancer, NSCLC is the leading cause of cancer deaths in the U.S. Until recently, there were no treatment options for NSCLC patients in whom chemotherapy failed. Iressa, which disables the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, was approved in 2003 for treatment of NSCLC even though it shrank tumors in less than 15 percent of patients because, in those whom it did help, responses were rapid and dramatic.

In 2004 MGH Cancer Center researchers and a team from Dana-Farber Cancer Institute both discovered why Iressa's success was confined to a limited group of patients. Specific EGFR mutations that were probably responsible for a tumor's development also made the cancer sensitive to Iressa treatment. Subsequent to that announcement, the Laboratory for Molecular Medicine at the Harvard-Partners Center for Genetics and Genomics developed a test to screen for these sensitizing mutations.

Late in 2004 a collaborative group led by MGH investigators began the current study, designed to see whether using Iressa as an initial treatment for patients with a sensitizing EGFR mutation would improve treatment results. Out of 98 NSCLC patients screened at 11 centers -- including the MGH Cancer Center and DFCI -- over a two-year period, 34 had a sensitizing mutation. Of those, 31 entered the trial and began receiving daily oral doses of Iressa instead of standard chemotherapy. Iressa treatment continued indefinitely unless significant side effects occurred or tumor growth continued or resumed.

All but two of the participants responded positively to Iressa treatment, with their tumors either shrinking significantly or not growing for a month or longer. At the end of the study period, 14 patients had died but 17 remained alive. The overall survival rate and the length of time until participants' tumors resumed growing were two or three times greater than would be expected with standard chemotherapy, Sequist explains. Only one participant dropped out because of treatment side effects.

The current study also analyzed the specific EGFR mutations in participants' tumors to see if there were differences in the response to treatment. Patients with the two most typical mutations had vigorous responses to Iressa, but the seven patients found to have atypical mutations had a more limited response. None of the atypical cases had tumor shrinkage, but the majority had disease stabilization for a period of time. Two patients who experienced rapid regrowth of their cancers were found to have additional EGFR mutations that previous research had indicated conferred resistance to the drug. It has been theorized that those resistance mutations develop in response to treatment, but this is the first observation of the mutations' being present before treatment began.

"It's starting to look like the strategy of genomically-directed cancer therapy will need to incorporate testing for multiple genotypes -- screening for three, four or even more genetic markers, some of which may indicate likelihood of response to treatment, and others the chance of resistance," says Sequist. "We think these results will also apply to other effective EGFR inhibitors, and we hope they can be duplicated for other types of cancer that involve these mutations. But what is needed next is a larger-scale, randomized clinical trial comparing an EGFR blocker with standard therapy in a genotype-selected population." Sequist is an instructor in Medicine at Harvard Medical School.

The report appears in the May 20 Journal of Clinical Oncology. Although Iressa is currently not being marketed in the U.S., the trial reported in this article was supported by AstraZeneca, the drug's manufacturer. Several other EGFR inhibitors, including Tarceva (erlotinib), are either on the market or in clinical trials.

Thomas J. Lynch, MD, chief of MGH Hematology and Oncology and director of the Center for Thoracic Cancers, is the senior author of the Journal of Clinical Oncology report. Other co-authors are Victoria Joshi, PhD, Alona Muzikansky, Georgiana Kuhlmann, Moon Han, Jeffrey Settleman, PhD, John Iafrate, MD, PhD, Jeffrey Engelman, MD, and Daniel Haber, MD, PhD, MGH Cancer Center; Pasi Janne, MD, PhD, and Bruce Johnson, MD, Dana-Farber Cancer Institute; Renato Martins, MD, MPH, University of Washington; David Spigel, MD, Sarah Cannon Research Institute, Nashville; Steven Grunberg, MD, University of Vermont School of Medicine; Alexander Spira, MD, Fairfax-Northern Virginia Hematology-Oncology; David McCollum, MD, Texas Oncology/Sammons Cancer Center, Dallas; Tracey Evans, MD, University of Pennsylvania; and Jonathan Goldberg, MD, Mt. Kisco (N.Y.) Medical Group.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "Determining Genetic Signature Of Lung Tumors Can Help Guide Treatment." ScienceDaily. ScienceDaily, 22 May 2008. <www.sciencedaily.com/releases/2008/05/080520103424.htm>.
Massachusetts General Hospital. (2008, May 22). Determining Genetic Signature Of Lung Tumors Can Help Guide Treatment. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2008/05/080520103424.htm
Massachusetts General Hospital. "Determining Genetic Signature Of Lung Tumors Can Help Guide Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/05/080520103424.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins